These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 3937059)

  • 21. Deprenyl (selegiline): the history of its development and pharmacological action.
    Knoll J
    Acta Neurol Scand Suppl; 1983; 95():57-80. PubMed ID: 6428148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of various monoamine oxidase (MAO) inhibitors on the response of blood pressure of rats and cats to tyramine.
    Abdo-Rubo A
    Acta Physiol Hung; 1990; 75(4):321-36. PubMed ID: 2127505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SR 95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. I. Psychopharmacological profile in rodents.
    Worms P; Kan JP; Wermuth CG; Roncucci R; Bizière K
    J Pharmacol Exp Ther; 1987 Jan; 240(1):241-50. PubMed ID: 3100770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective pressor enhancement by monoamine oxidase inhibitors in conscious rats.
    Kerecsen L; Bunag RD
    J Pharmacol Exp Ther; 1989 Nov; 251(2):645-9. PubMed ID: 2509682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.
    Fuller RW; Hemrick-Luecke SK; Kindt MV; Heikkila RE
    Life Sci; 1988; 42(3):263-71. PubMed ID: 3121972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative ex vivo inhibitory effects of (E)-2-(3,4-dimethoxyphenyl)-3-fluoroallylamine (MDL 72145) on amine oxidase activities in the rat.
    Lyles GA; Marshall CM; Flucker CJ
    Biochem Pharmacol; 1989 Sep; 38(17):2937-40. PubMed ID: 2775316
    [No Abstract]   [Full Text] [Related]  

  • 29. Cardiovascular changes in response to selective monoamine oxidase inhibition in the rat.
    Cohen RM; Campbell IC; Yamaguchi I; Pickar D; Kopin IJ; Murphy DL
    Eur J Pharmacol; 1982 May; 80(1):155-60. PubMed ID: 6284529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl.
    Riederer P; Youdim MB
    J Neurochem; 1986 May; 46(5):1359-65. PubMed ID: 2420928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
    Bitsios P; Langley RW; Tavernor S; Pyykkö K; Scheinin M; Szabadi E; Bradshaw CM
    Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of L-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake.
    Fang J; Yu PH
    Neuropharmacology; 1994 Jun; 33(6):763-8. PubMed ID: 7936114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacology of (-)deprenyl.
    Knoll J
    J Neural Transm Suppl; 1986; 22():75-89. PubMed ID: 3097262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deprenyl antagonizes acute lethality of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
    Fuller RW; Hemrick-Luecke SK; Perry KW
    J Pharmacol Exp Ther; 1988 Nov; 247(2):531-5. PubMed ID: 3141609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Cardiovascular effects of (+)- and (-)-tranylcypromine compared to other monoamine oxidase inhibitors in animal studies (author's transl)].
    Dénes B; Greeff K; Tawfik H
    Arzneimittelforschung; 1982; 32(3):201-7. PubMed ID: 6805481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lesion-induced reductions in trace amine accumulation: dependence on MAO inhibitor pretreatment.
    Nguyen TV; Juorio AV; Greenshaw AJ
    Brain Res Bull; 1989 Feb; 22(2):197-200. PubMed ID: 2495844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic aspects of deprenyl effects.
    Magyar K; Tóthfalusi L
    Pol J Pharmacol Pharm; 1984; 36(4):373-84. PubMed ID: 6441926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl.
    Bondiolotti GP; Galva MD; Villa F; Sciaba L; Picotti GB
    Biochem Pharmacol; 1995 Jun; 50(1):97-102. PubMed ID: 7605351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tyramine pressor sensitivity changes during deprenyl treatment.
    Sunderland T; Mueller EA; Cohen RM; Jimerson DC; Pickar D; Murphy DL
    Psychopharmacology (Berl); 1985; 86(4):432-7. PubMed ID: 3929314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzyme-activated irreversible inhibitors of monoamine oxidase: phenylallylamine structure-activity relationships.
    McDonald IA; Lacoste JM; Bey P; Palfreyman MG; Zreika M
    J Med Chem; 1985 Feb; 28(2):186-93. PubMed ID: 3968682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.